SCHEMBL18358985

SCHEMBL18358985

Cc1nc(-c2ccc(S(N)(=O)=O)cc2)cs1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.62
BLM P54132 1/20 0.60
HTT P42858 3/20 0.59
RAB9A P51151 3/20 0.59
LMNA P02545 1/20 0.59
TSHR P16473 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
HPGD P15428 2/20 0.59
MAPT P10636 7/20 0.56
PTGS2 P35354 1/20 0.55
GAA P10253 3/20 0.54
KDM4E B2RXH2 2/20 0.54
POLB P06746 2/20 0.54
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
MAPK1 P28482 2/20 0.53
TP53 P04637 1/20 0.53
THRB P10828 1/20 0.53
ALOX15 P16050 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL956179 0.85 ALDH1A1 (0.64) ALDH1A1BLMHTTRAB9ALMNA
SCHEMBL19626644 0.85 HPGD (0.65) ALDH1A1BLMHTTRAB9ALMNA
SCHEMBL2430700 0.83 MAPT (0.58) ALDH1A1HTTRAB9ALMNAMAPT
Hydrochloric Acid SCHEMBL16991024 0.82 ALDH1A1 (0.62) ALDH1A1BLMHTTRAB9ALMNA
SCHEMBL19627024 0.81 ALDH1A1 (0.72) ALDH1A1BLMHTTRAB9ALMNA
SCHEMBL19976508 0.81 MAPT (0.64) ALDH1A1BLMHTTRAB9ALMNA
SCHEMBL6798064 0.80 HPGD (0.55) ALDH1A1HTTRAB9ALMNATSHR
SCHEMBL27150019 0.80 PTGS2 (0.49) ALDH1A1BLMHTTRAB9ALMNA
SCHEMBL17073215 0.77 ALDH1A1 (1.00) ALDH1A1HTTRAB9ALMNATSHR
SCHEMBL225793 0.77 RECQL (0.64) ALDH1A1HTTRAB9ATSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER BAYER AKTIENGESELLSCHAFT (DE) 2024-08-22 US disclosed
EP-4229048-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER The Broad Institute, Inc. (US) 2023-08-23 EP disclosed
WO-2022081807-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. (US) 2022-04-21 WO disclosed
EP-2900638-B1 COMPOUNDS FOR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS UNIVERSITÉ DE DROIT ET DE LA SANTÉ DE LILLE 2 (FR) 2017-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279207-A1 SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A ALDH1A1 985/4885BLM 2530/4885HTT 1681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.